Direct Biologics LLC, a biotechnology company in the late stages of development, has recently published groundbreaking findings from their Phase 2 clinical trial in the prestigious Journal CHEST. The trial focused on evaluating the effectiveness of ExoFlo™, a regenerative medicine platform that utilizes extracellular vesicles (EVs) derived from bone marrow-derived mesenchymal stem cells (BM-MSCs..
Liberate Medical Secures $6.2M in Series B Financing Series B Co-Led by a Large Strategic Investor and Scientific Health Development to Support the Pivotal Clinical Trial of the VentFree® Respiratory Muscle Stimulator CRESTWOOD, Ky.--(BUSINESS WIRE)-- Liberate Medical, an emerging leader in the development of novel non-invasive neurostimulation devices focused on transforming respiratory care, a..
InnoCare Pharma (HKEX: 09969; SSE: 688428) has announced that the first psoriasis patient has been dosed in a clinical trial of their TYK2 allosteric inhibitor ICP-488 in China. The phase I clinical trial has already completed single ascending doses (SAD) and multiple ascending doses (MAD) of ICP-488, showing a well-tolerated safety profile. The ongoing study aims to evaluate the safety and effi..
Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder   Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patients. PORTICO plans to recruit 188 patients.   MADRID, Spain and BOSTON, July 05, 2023 (GLOBE NEWSWIRE) -- ..
Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, has announced positive topline results from its first Phase 1 clinical study of FB101. This investigational vaginal microbial immunotherapeutic has shown promising results in treating asymptomatic vaginal dysbiosis. The study was conducted in Europe and evaluated the change in vaginal microbiome after three conse..
TransCode Therapeutics has announced new data supporting the use of TTX-MC138 for the treatment of metastatic breast cancer. The RNA oncology company's lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b, described as the master regulator of cancer progression in a number of advanced solid tumors including breast cancer. In a preclinical model of pancreatic adenocarcinoma,..
TransCode Therapeutics has published new data supporting the use of TTX-MC138 for the treatment of metastatic breast cancer. The lead therapeutic candidate, designed to inhibit microRNA-10b, has been shown to impair the capacity of cancer stem cells to create new tumors and become metastatic in breast cancer cells. Inhibiting these cells could improve outcomes in patients with recurrent and resi..
